Evaluation of the effect of a herbal mixture on non alcoholic fatty liver disease

Evaluation of the effects of a Polyherbal compound on severity of steatosis and the levels of blood lipids and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015123025772N1

Enrollment

Registered

2016-04-08

Start date

2016-04-20

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver desease. Fatty (change of) liver, not elsewhere classified

Interventions

The treatment group received herbal capsules containing 400 mg of the mixture of Anethum graveolens, Citrus bigardia, Cynara scolymus, Portulaca oleracea, and Silybum marianum (2 capsules, thrice dail

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: patients with nonalcoholic fatty liver disease with grade = 2 of steatosis on sonography or grade 1 of steatosis + elevated serum alanine transaminase level

Exclusion criteria

Exclusion criteria: Having special or chronic disease like auto immune diseases, hypothyroidism, lupus, renal dysfunction, cancers, heart diseases, and severe infections Cirrhosis or Hepatitis B and C Pregnancy and lactation Unwillingness to continue treatment with herbal compound

Design outcomes

Primary

Measure	Time frame
Alanine transaminase (ALT). Timepoint: Before intervention, two month after intervention. Method of measurement: Blood examination.;Steatosis of liver. Timepoint: Before intervention, two month after intervention. Method of measurement: Sonography.	—

Secondary

Measure	Time frame
Aspartate transaminase (AST). Timepoint: Before starting study and 2 months after starting study. Method of measurement: Blood analysis (kit).;Fasting blood glucose. Timepoint: Before starting study and 2 months after starting study. Method of measurement: Blood analysis (kit).;Serum lipids. Timepoint: Before starting study and 2 months after starting study. Method of measurement: Blood analysis (kit) for total cholesterol and triglyceride.	—

Measure

Time frame

Aspartate transaminase (AST). Timepoint: Before starting study and 2 months after starting study. Method of measurement: Blood analysis (kit).;Fasting blood glucose. Timepoint: Before starting study and 2 months after starting study. Method of measurement: Blood analysis (kit).;Serum lipids. Timepoint: Before starting study and 2 months after starting study. Method of measurement: Blood analysis (kit) for total cholesterol and triglyceride.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Abbas Zojaji

Zojaj darman toos Pharmaceutical Company

zojajclub@gmail.com+98 51 3502 4824

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026